Prof. Dr. Kuikun Yang | Nanotechnology | Research Excellence Award
Professor | Harbin Institute of Technology | China
Prof. Dr. Kuikun Yang is a distinguished researcher at Harbin Institute of Technology whose work centers on nanomedicine, biomedical nanomaterials, and advanced therapeutic platforms. His research interests include MOF-based nanocomposites, quantum dot–functional materials, lipid nanoparticles for mRNA delivery, supramolecular polymers, ROS-responsive systems, photothermal therapy, ferroptosis, and synergistic cancer treatments. He possesses strong research skills in nanomaterial design, stimuli-responsive drug delivery, tumor microenvironment modulation, translational nanotechnology, and interdisciplinary integration of chemistry, materials science, and biomedicine. Prof. Yang has received academic recognition and research honors through high-impact publications, invited reviews, and leadership in collaborative international research. According to Scopus, he has authored 41 documents, accumulated 2,706 citations, and achieved an h-index of 26, demonstrating sustained scholarly impact. In conclusion, Prof. Dr. Kuikun Yang’s innovative contributions continue to advance precision oncology and next-generation nanotherapeutic strategies with strong translational potential.
2,706
41
26
Citations
Documents
h-index
View Scopus Profile View Google Schola Profile View ORCID Profile
Featured Publications
Polyprodrug nanomedicines: an emerging paradigm for cancer therapy
– Advanced Materials, 2022 (Citations: 136)
Neutrophil membrane-camouflaged polyprodrug nanomedicine for inflammation suppression in ischemic stroke therapy
– Advanced Materials, 2024 (Citations: 109)
A hypoxia responsive nanoassembly for tumor-specific oxygenation and enhanced sonodynamic therapy
– Biomaterials, 2021 (Citations: 107)
Polymers and inorganic nanoparticles: A winning combination towards assembled nanostructures for cancer imaging and therapy
– Nano Today, 2021 (Citations: 107)
Oxygen-evolving manganese ferrite nanovesicles for hypoxia-responsive drug delivery and enhanced cancer chemoimmunotherapy
– Advanced Functional Materials, 2021 (Citations: 105)